261 results about "Umbilical cord" patented technology

The invention discloses a cord blood-derived regulatory T cell amplification culture medium and a use method thereof, and relates to the field of animal cell culture and immune cell therapy, the culture medium is a serum-free culture medium, the culture medium is composed of a basic culture medium, a serum substitute combination, a combination of four cell factors, an immunosuppressor, an apparent stabilizer and an antioxidant, and all the components play a role synergistically; according to the use method, cell amplification is realized through a collaborative process of staged environmental regulation and targeted activation. According to the method, the problems of exogenous pollution and batch difference caused by dependence of a serum-containing system on cord blood-derived regulatory T cell amplification in the prior art are solved, the defect that a serum-free scheme is difficult to consider the amplification efficiency and the function stability at the same time is overcome, the cell amplification quality and the clinical application safety are guaranteed, and the method is suitable for large-scale clinical transformation requirements.

The invention discloses application of a stem cell exosome in treating depression-like behaviors caused by high-altitude hypoxia, and belongs to the technical field of biomedicine. The stem cell exosome is an exosome derived from human umbilical cord mesenchymal stem cells, and is used for drugs for preventing and / or treating depression-like behaviors caused by high-altitude hypoxia. The exosome can effectively improve depression-like core behavior symptoms caused by high-altitude hypoxia by regulating a brain-intestinal axis; the method starts from remodeling intestinal flora so as to influence the intracerebral metabolite spectrum, and finally plays a role in neuroprotection by regulating and controlling a 5-HT6 / cAMP-PKA key signal channel. In addition, the combination of the hUC-MSC-exo and probiotics shows synergistic interaction potential, and a potential treatment strategy which is novel in mechanism, remarkable in effect and high in safety is provided for the field.

The invention relates to the technical field of rhinitis spray preparation, in particular to a method for preparing allergic rhinitis spray from umbilical cord mesenchymal stem cell exosomes, which comprises the following steps: 1, umbilical cord treatment; 2, culturing umbilical cord mesenchymal stem cells; 3, preparing an umbilical cord mesenchymal stem cell exosome; and 4, preparing the rhinitis spray. The rhinitis spray prepared by the method disclosed by the invention is simpler and more convenient to use. The exosome, the platelet growth factor and other substances in the rhinitis spray well solve the core problems of single curative effect, large side effect, low compliance and the like in the traditional rhinitis treatment, and through the induction and repair functions of the stem cell exosome and the bactericidal ability of the antibacterial peptide, the nasal cavity environment is improved, the anaphylactic reaction is reduced, the nasal mucosa is repaired, and the rhinitis treatment effect is improved. The allergic rhinitis is expected to be fundamentally treated.

The invention relates to a bioactivity-related characteristic marker of umbilical cord mesenchymal stem cell-derived small extracellular vesicles and application of the bioactivity-related characteristic marker. The bioactivity-related characteristic marker of the umbilical cord mesenchymal stem cell-derived small extracellular vesicles comprises one or a combination of more than two of a PSMB3 protein, an SAA4 protein, a VPS33B protein and an AKR7A2 protein. The invention provides a screening method of the characteristic markers, and particularly, the biological activity of the human umbilical cord mesenchymal stem cell source extracellular vesicles can be effectively judged by detecting the characteristic markers or the combination of the characteristic markers of the umbilical cord mesenchymal stem cell source extracellular vesicles. An evaluation means and an important reference are provided for product quality control, clinical transformation and the like based on the umbilical cord mesenchymal stem cell-derived small extracellular vesicles.

The invention discloses a PDRN-loaded umbilical cord mesenchymal stem cell source nano-vesicle and a preparation method thereof, and belongs to the technical field of biological medicines. The preparation method provided by the invention comprises the following steps: mixing an umbilical cord mesenchymal stem cell suspension with a PDRN solution, and carrying out freeze thawing treatment; incubating the mixed solution subjected to freeze thawing treatment; extruding the incubated mixed solution for multiple times by using a filter membrane; and collecting the extruded product, and separating and purifying to obtain the PDRN-loaded umbilical cord mesenchymal stem cell source nano-vesicle. According to the preparation method disclosed by the invention, the encapsulation efficiency of PDRN is remarkably improved, meanwhile, secondary damage of a traditional post-loading technology to a preformed vesicle structure is avoided, the membrane integrity and biological activity of a final product are better maintained, the yield is high, and the preparation process is rapid; the introduction of exogenous impurities is avoided from the source, and the high purity and biological safety of the obtained nano-vesicle component are ensured.

The invention relates to the technical field of bioengineering, in particular to a preparation method of a probiotic and exosome preparation applied to immunoregulation. The probiotics and the umbilical cord stem cell exosome are combined for use, the immune regulation effect is enhanced from multiple targets and multiple ways, the immune function of the body is improved, the exosome carries a specific molecular marker and acts on immune cells in a targeted mode, precise immune regulation is achieved, and the preparation is in an oral form and convenient to use; the exosome is extracted from umbilical cord stem cells, has no pathogenicity and immunogenicity, and is low in adverse reaction risk after being used for a long time, and the prepared combined preparation can be used for treating and preventing various immune-related diseases, and also can be used for daily conditioning of people with low immunity and improving the body resistance; meanwhile, the combined preparation adopts micro-capsule embedding, so that the probiotics can be effectively protected from gastric acid and bile erosion, the survival rate and colonization efficiency of the probiotics in intestinal tracts are improved, the immunoregulation effect is further enhanced, and the combined preparation is convenient to store and transport and has a good application prospect.

The invention relates to the technical field of cosmetics, and discloses an umbilical cord blood moisturizing essence composition, an umbilical cord blood moisturizing essence as well as a preparation method and application of the umbilical cord blood moisturizing essence. The composition contains a hydrolyzed placenta extract, placenta protein, an umbilical cord extract, a guava fruit extract, a radix gentianae extract, decapeptide-4, nonapeptide-1, a lactobacillus fermentation product and a yeast fermentation product filtrate. The umbilical cord blood moisturizing essence prepared from the composition has multiple effects of moisturizing, repairing and resisting aging, and is mild, safe, excellent in stability and high in active ingredient retention rate.

The invention relates to the technical field of biomedical information, in particular to an umbilical cord mesenchymal stem cell donor matching database construction method based on HLA (human leukocyte antigen) typing, which comprises the following steps of: recording and storing data of a donor in a database to finish initial construction of the database; regularly rechecking the donor data record stored in the database, and updating the state identifier of the donor data record when the rechecked data is changed by a preset degree; and receiving a matching request containing the human leukocyte antigen typing data of the target patient and the target disease type, performing donor screening in the database by using a preset comprehensive matching degree model based on the matching request, and optimizing parameters of the comprehensive matching degree model through a machine learning model based on the matching record and the clinical curative effect data corresponding to the matching record. According to the method, the accuracy and effectiveness of umbilical cord mesenchymal stem cell treatment are improved, and meanwhile, the system has continuous self-evolution ability.

The invention relates to the field of cell engineering and gene engineering, in particular to a method for enhancing the multiplication capacity of umbilical cord mesenchymal stem cells and application. The expression or activity of the STN1 gene in the umbilical cord mesenchymal stem cells is reduced through an accelerant, and the umbilical cord mesenchymal stem cells with enhanced multiplication capacity are obtained. By knocking down the hUC-MSCs of STN1, the proliferation speed of the hUC-MSCs is higher, DNA replication is more active, the clone formation ability is higher, and the aging proportion of the hUC-MSCs can be remarkably reduced.

This invention discloses recombinant umbilical cord mesenchymal stem cells related to pentamericin 3 in the field of genetic engineering, their preparation method, and applications. The technical problem this invention aims to solve is how to provide a cell product capable of treating bone regeneration insufficiency. To solve this technical problem, this invention provides recombinant umbilical cord mesenchymal stem cells, which are prepared according to a method comprising the following steps: upregulating or enhancing or increasing the content and / or activity of pentamericin 3 or the expression of the gene encoding said protein in the umbilical cord mesenchymal stem cells, thereby obtaining the recombinant umbilical cord mesenchymal stem cells. The recombinant umbilical cord mesenchymal stem cells provided by this invention can be used to treat diseases related to bone regeneration insufficiency.

The invention discloses a culture method for inducing high expression of umbilical cord mesenchymal stem cells (LRP1) and application, and belongs to the technical field of biological medicines. The technical problem to be solved is to provide a standardized culture method for directionally inducing a specific functional phenotype cell population, so that efficient and accurate induction of LRP1 high-expression UCMSCs is realized, and clinical adaptation is met. According to the key point of the technical scheme, the culture method for inducing the LRP1 high-expression umbilical cord mesenchymal stem cells comprises the following steps: inoculating umbilical cord mesenchymal stem cells into a culture dish at the inoculation density of 5.5 * 10 < 3 > / cm < 2 > to 3.6 * 10 < 4 > / cm < 2 >, and culturing for 24-72 hours by using a special mesenchymal stem cell culture medium without adding a supplement, so that the acquisition efficiency of the LRP1 high-expression UCMSCs is improved, and the yield of the LRP1 high-expression UCMSCs is increased. Antibody labeling and flow sorting are not needed, so that the operation steps are simplified, and the complexity and cost of the culture process are reduced.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The present invention relates to a composition and method for treating rheumatoid arthritis, comprising interleukins (ILs), including IL-1β, stimulated human umbilical cord mesenchymal stem cells (hUCMSCs). The IL stimulated hUCMSCs of the present invention may induce the apoptosis of fibroblast-like synoviocytes rheumatoid arthritis (HFLS-RA) cells. IL stimulated hUCMSCs are useful to alleviate RA symptoms, such as inflammation, swelling and cartilage erosion, and exhibit therapeutic effects on rheumatoid arthritis.

The invention discloses a serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and application thereof. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition is prepared from the following components in parts by mass: 15 to 25 parts of platelet-derived growth factor-BB; 15 to 25 parts of basic fibroblast growth factors; 8 to 12 parts of transforming growth factor-beta; and 8-12 parts of recombinant human insulin. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and the application thereof disclosed by the invention have the following beneficial effects: (1) the proliferation efficiency is remarkably improved; (2) the cell morphology and dryness can be well maintained; and (3) the compliance and the compatibility are good.

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

This invention belongs to the field of biomedical technology, specifically relating to a rapid purification method for umbilical cord MSC exosomes and their application in the preparation of drugs for treating COPD. This invention discloses a method for rapidly purifying umbilical cord mesenchymal stromal cell (MSC) exosomes and a pharmaceutical composition comprising umbilical cord MSC exosomes and yamosaponin. In this pharmaceutical composition, the umbilical cord MSC exosomes and yamosaponin synergistically enhance the dynamic compliance of COPD rats, reduce airway resistance, decrease pulmonary inflammation, and repair pulmonary dysfunction. This invention provides a new technical solution for the preparation of drugs for treating or improving COPD.

The invention provides an application of miR-337 in preparation of a medicine for treating osteoporosis, which is used for the medicine for treating osteoporosis, and relates to the technical field of biomedicine. The research of the inventor finds that miR-337 can activate p53 to promote apoptosis of osteoclasts, has a certain treatment effect on osteoporosis, and can be used for preparing the medicine for treating osteoporosis; the nano vesicles derived from human umbilical cord mesenchymal stem cells have certain anti-inflammatory activity and have a positive effect on treatment of osteoporosis. According to the application disclosed by the invention, miR-337 is further loaded on nano vesicles derived from human umbilical cord mesenchymal stem cells, and the research of the inventor finds that the medicine has a good treatment effect on osteoporosis, provides a new strategy for preventing postmenopausal osteoporosis, and has remarkable clinical transformation potential.

The invention belongs to the technical field of biomedicine, and particularly relates to an overexpression miR-141-3p exosome as well as a preparation method and application thereof. The exosome is derived from mesenchymal stem cells; the nucleotide sequence of the miR-141-3p is as shown in SEQ ID NO: 1 (Sequence Identity Number 1). According to the overexpression miR-141-3p exosome provided by the invention, the exosome can be produced on a large scale, the difference between batches is small, the targeting property is strong, and the overexpression miR-141-3p immortalized umbilical cord mesenchymal stem cell exosome provides a new scheme for clinical treatment of hepatocellular carcinoma.

The curcumin-coupled copper-gold bimetallic nanoszyme AuCu-Cur prepared by the application can remove ROS and relieve oxidative stress, prevent further damage to DNA, and introduce human umbilical cord mesenchymal stem cell-derived extracellular vesicles (hUCMSC-EVs) to improve the bioavailability. In the system, curcumin can repair damaged DNA by promoting the expression of NEIL3. In addition, the vesicles themselves are rich in various tissue repair-related proteins and RNAs, which can promote DNA replication of notochordal cells (NPCs), reverse the aging state and stimulate extracellular matrix synthesis. In the IVDD model induced by rat tail vertebra puncture, we confirmed that the material has strong antioxidant and DNA repair capacity and can effectively delay cell aging, thereby relieving the progression of IVDD. Compared with existing intervertebral disc biomaterial treatments, the present scheme can realize continuous DNA repair, which is an active, multi-target repair program that not only interrupts the vicious cycle of intervertebral disc degeneration but also promotes tissue transformation to regeneration.

The utility model relates to the technical field of biological experiment instruments, in particular to a hanging accessory used in the separation process of umbilical cord blood hematopoietic stem cells, which is mainly used for being connected with a grid at the top of a biological safety cabinet and comprises a fixed end connected with the grid at the top of the biological safety cabinet, and a hook used for being connected with a blood bag is arranged below the fixed end. The fixing end comprises a clamping ring, a torsional spring clamping opening capable of being clamped into a grid is formed in the clamping ring, a limiting sliding groove is formed in the inner side of the clamping ring, and a limiting rod capable of moving up and down along the inner wall of the clamping ring is slidably connected into the limiting sliding groove. A reset spring capable of resetting the limiting rod upwards is arranged between the bottom of the limiting sliding groove and the limiting rod. The technical problems that in the prior art, a blood bag is connected with a grid in a biological safety cabinet through a paper clip, then the blood bag is hung, shaking is large, the blood bag is prone to falling off, a sample possibly needs to be centrifuged many times, and the motility rate of the sample is affected are solved.

The present application relates to the technical field of biological medicine, in particular to a kind of umbilical cord-derived mesenchymal stem cell exosome preparation, preparation method and application in preparation of osteoarthritis drugs.The preparation is prepared by the method.The method comprises pretreating umbilical cord-derived mesenchymal stem cells with a pretreatment agent;discard the pretreatment agent, and gradient centrifugation treatment is carried out to the pretreated umbilical cord-derived mesenchymal stem cells, to obtain exosome precipitate;the exosome precipitate is resuspended in a buffer containing protease inhibitor to obtain umbilical cord-derived mesenchymal stem cell exosome preparation.The application is the application of the preparation in the preparation of osteoarthritis drugs.The present application solves the problems of low yield and functional heterogeneity of EXO obtained by conventional culture method.

Disclosed herein is a formulation comprising an extracellular vesicle (EV), and a therapeutic active agent induced or embedded in the EV. According to preferred embodiments of the present disclosure, the EV is isolated from umbilical cord mesenchymal stem cells, and the active agent may be a growth factor, an immune-modulating agent, a small molecule, an siRNA, cDNA or a plant ingredient; for example, curcumin. Also disclosed herein are methods for producing the present formulation, and uses of the present formulation in the treatment of various diseases.

The utility model relates to the technical field of culture dishes, in particular to an umbilical cord stem cell culture dish convenient to store and take, which comprises a box body, a plugging cover, a first connecting plate and a second connecting plate, the upper end of the box body is connected with the plugging cover in a clamping manner, the plugging cover is connected with a sealing mechanism, one side of the box body is connected with the first connecting plate, and the second connecting plate is connected with the second connecting plate. The other side of the box body is connected with a second connecting plate, a first limiting mechanism is arranged on the side edge of the first connecting plate, and a clamping mechanism is arranged on the side edge of the second connecting plate. In the using process, the plugging cover is connected with the box body in a clamped mode, then the bolt is rotated to drive the plugging plate to ascend to suck air in the box body, so that the plugging cover and the box body are clamped more tightly, the sealing performance of the device is improved, and when the plugging cover needs to be taken down, the plugging block is taken down at the moment; and then the gas enters the box body through the circular groove and the circular column, so that the plugging cover can be easily taken down and is convenient to store and take.

The upper surgical field for cesarean section intervention with neonatal transfer aims to eliminate the current limitations of the "humanized cesarean" by creating a circuit for direct transfer of the newborn to its mother within the surgical field and without altering asepsis. This internal communication is achieved by means of a sterile main drape with a fenestration in its caudal portion that continues perpendicularly with a transfer module located over the maternal thorax, a non-sterile area, with an integrated closure system. Additionally, the main drape has a secondary drape designed to seal the fenestration. This surgical field allows for maintaining sterility during neonatal transfer, optimizes delayed clamping of the umbilical cord, ensures the preservation of heat and continuous visualization of the newborn, achieves immediate skin-to-skin contact, and increases maternal participation in welcoming the newborn.

This invention discloses a culture medium, preparation method, and culture method for the industrial-scale preparation of mesenchymal stem cells, belonging to the field of cell therapy technology. The culture medium comprises a basal medium, cell growth factors, cell proliferation promoters, a vitamin mixture, a nucleoside mixture, and an amino acid mixture; wherein the cell growth factors are selected from one or more of TGF-β, bFGF, VEGF, PDGF, EGF, and IGF. Through the synergistic effect of the composite nutrient system, this invention significantly improves the proliferation rate and cell viability of mesenchymal stem cells, maintains stem cell stemness, trilineage differentiation ability, and secretion levels of key cytokines (VEGF, HGF, TGF-β, IL-10, etc.); it can be stably and continuously passaged up to the 15th generation without abnormal changes in genetic material. This culture medium contains no animal-derived components, has high batch-to-batch stability, and is cost-controllable, making it suitable for GMP-level large-scale industrial preparation of mesenchymal stem cells from various sources such as umbilical cord, bone marrow, adipose tissue, and placenta.

The invention relates to the technical field of high-yield collagen MSC (mesenchymal stem cell) engineering construction, and particularly discloses a fixed-point controllable high-yield collagen MSC engineering construction method, which comprises the following steps: 1, MSC separation and primary culture: separating from mammal bone marrow, umbilical cord or adipose tissue to obtain primary MSC, adopting a DMEM / F12 culture medium containing 13% of fetal calf serum, and carrying out primary culture on the primary MSC; carrying out primary culture and passage in a culture environment of 37 DEG C and 5% CO, and screening the fourth generation of MSC in the logarithmic phase as an engineered starting cell; and 2, constructing a collagen synthesis related gene fixed-point editing carrier: designing a fixed-point editing element aiming at a collagen synthesis key gene and an MSC differentiation regulation gene. According to the site-specific controllable high-yield collagen MSC engineering construction method, the collagen expression quantity of the engineered MSC can be greatly improved, the directional synthesis proportion of the type I collagen and the type III collagen is improved, and the requirement of industrialization for high-yield and high-purity collagen is effectively met.

This application relates to the field of gene transduction technology, specifically disclosing a method and application for modifying mesenchymal stem cells (MSCs) targeting myocardial injury. The method includes: S1, obtaining umbilical cord-derived MSCs; S2, performing surface biomimetic modification on the MSCs; S3, gene editing on the MSCs; and S4, co-incubating the engineered MSCs with enzyme-responsive liposomes loaded with nitric oxide donors. The liposomes are embedded in a gelatin coating on the cell membrane surface through hydrophobic interactions, forming a targeted therapeutic system. This method for modifying MSCs targeting myocardial injury can be used for regenerative therapy and repair of myocardial injury diseases such as myocardial infarction and ischemic heart disease. It comprehensively improves the survival and stress tolerance of cells after implantation and enhances the targeting precision to the damaged site, thereby achieving the advantages of efficient, precise, and highly adaptable myocardial repair.

The invention relates to the technical field of biomedical detection, and discloses an umbilical cord blood unfreezing reference specimen cell counting and flow cytometry dilution method which comprises the following steps: S1, preparing an unfreezing solution which is composed of HES, AB plasma and PBS, and placing the unfreezing solution at room temperature for later use; s2, taking the unfrozen umbilical cord blood unfreezing reference specimen, adding an unfreezing solution into the umbilical cord blood, firstly gently and uniformly mixing, then standing at room temperature, then continuing to add the unfreezing solution, gently and uniformly mixing again, then standing at room temperature, and stabilizing; s3, taking the diluted umbilical cord blood, and carrying out cell counting by adopting a counting instrument; and S4, taking the diluted umbilical cord blood again, and dyeing. The unfreezing solution composed of HES, AB plasma and PBS synergistically regulates osmotic pressure, provides cell nutrition, stabilizes the pH value, reduces the damage of the cryoprotectant to cord blood cells, maintains the cell activity, and improves the problem of result deviation caused by direct detection of cell damage in the prior art.

The invention relates to the field of biomedicine, and discloses application of EPTMPA in hematopoietic stem cell in-vitro amplification culture. The invention identifies a brand-new novel small molecule compound EPTMPA capable of remarkably promoting in-vitro expansion and in-vivo transplantation of hematopoietic stem cells and hematopoietic progenitor cells of umbilical cord blood, and the novel small molecule compound EPTMPA can remarkably promote in-vitro expansion of CD34 + hematopoietic stem cells and hematopoietic progenitor cells and maintain the stem property and differentiation potential. EPTMPA is a new discovery and new way for in-vitro amplification of hematopoietic stem cells, but needs more studies to understand the action mechanism, targeting genes and proteins of the hematopoietic stem cells and the regulation effect on self-renewal and differentiation balance of the stem cells. The researches are of great significance to clinical application and product development in the future.

The application belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of umbilical cord blood plasma-derived extracellular vesicles and related bioactive molecules thereof in treatment of Alzheimer's disease. Specifically, the application isolates extracellular vesicles (UCBP-sEVs) from umbilical cord blood plasma, which has the effect of improving Alzheimer's disease. Further research finds that high enrichment of miR-16-2-3p therein is a key molecule for mediating treatment of Alzheimer's disease. miR-16-2-3p targets and inhibits expression of ROCK2, reduces phosphorylation level of TFEB and promotes nuclear translocation of the same, activates microglial autophagy-lysosome pathway, and thus promotes phagocytosis and degradation of intracerebral beta amyloid, and therefore has good practical application value.